TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
BeiGene, Ltd. - American Depositary Shares (ONC)
Company Research
Source: Business Wire
New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemotherapy SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (=1).“The approval of TEVIMBRA in combination with chemot
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- Beigene, Ltd. (NASDAQ: ONC) was given a new $259.00 price target on by analysts at Sanford C. Bernstein.MarketBeat
- Beigene, Ltd. (NASDAQ: ONC) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Beigene, Ltd. (NASDAQ: ONC) was given a new $348.00 price target on by analysts at JMP Securities.MarketBeat
- TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy [Yahoo! Finance]Yahoo! Finance
- Beigene, Ltd. (NASDAQ: ONC) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $320.00 price target on the stock, up previously from $207.00.MarketBeat
ONC
Earnings
- 2/27/25 - Miss
ONC
Sec Filings
- 3/20/25 - Form 4
- 3/18/25 - Form 4
- 3/13/25 - Form 4
- ONC's page on the SEC website